# Aconitine (from Aconitum species)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/aconitine-from-aconitum-species
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** Aconitum alkaloid, Acetylbenzoylaconine, C₁₉-diterpenoid alkaloid, Aconitina, Aconitin

## Overview

Aconitine (C₃₄H₄₇NO₁₁) exerts analgesic, [anti-inflammatory](/ingredients/condition/inflammation), and anti-tumor effects primarily through voltage-gated sodium channel modulation, NF-κB pathway suppression, and regulation of Bcl-2/Bax apoptotic signaling. Preclinical meta-analysis of 37 studies confirms significant tumor cell proliferation reduction and increased apoptosis, while structurally optimized derivatives such as bulleyaconitine A have entered clinical use as analgesics in China, though the narrow therapeutic index of native aconitine severely restricts human application.

## Health Benefits

- **Analgesic Activity**: Aconitine-type C₁₉ diterpenoid alkaloids bind to voltage-gated sodium channels, reducing neuronal excitability and pain signal transmission; two clinical-stage derivatives (compounds 15 and 37 class analogues, including bulleyaconitine A) are formulated pharmaceutical analgesics approved in China.
- **Anti-tumor Effects**: Aconitine inhibits tumor cell proliferation by regulating the NF-κB signaling pathway, modulating downstream Bcl-2 and Bax expression, and triggering autophagic cell death; a meta-analysis of 37 preclinical studies confirmed significant reductions in tumor proliferation and thymus index across multiple cancer models.
- **Anti-inflammatory Properties**: Through suppression of NF-κB activation, aconitine reduces transcription of [pro-inflammatory cytokine](/ingredients/condition/inflammation)s including TNF-α and IL-6, attenuating inflammatory cascades in preclinical in vitro and in vivo models.
- **Cardiac Modulation**: At sub-toxic concentrations, aconitine modulates cardiac electrophysiology by affecting sodium and calcium channel dynamics; studies on human iPSC-derived cardiomyocytes demonstrated measurable changes in calcium transient frequency at 5 μM, suggesting potential utility in understanding arrhythmia mechanisms.
- **Androgen Synthesis Inhibition**: In vitro exposure to 50 μM aconitine for 24 hours effectively suppressed androgen biosynthesis enzyme expression in relevant cell lines, indicating a potential endocrine-modulatory role with implications for hormone-sensitive conditions.
- **Apoptosis Induction in Cancer Cells**: Structurally modified aconitine scaffold compounds (e.g., compound 22a) impeded HepG2 hepatocellular carcinoma cell proliferation in a dose- and time-dependent manner, inducing apoptosis at higher concentrations through [mitochondrial](/ingredients/condition/energy) pathway dysregulation.
- **Hsp90 Inhibition (Derivative Activity)**: Optimized derivative compound 27 achieved an IC₅₀ of 0.71 nM against target tumor cells by occupying the deep ATP-binding pocket of Hsp90α, with its lactam group forming a hydrogen bond with Asn106, demonstrating that aconitine scaffolds can be engineered into potent chaperone inhibitors.

## Mechanism of Action

Aconitine's primary mechanism involves persistent activation and subsequent inactivation of voltage-gated sodium channels (Nav), particularly Nav1.4 and Nav1.7, shifting their activation threshold and prolonging depolarization, which accounts for both its analgesic properties at low doses and its cardiotoxic and neurotoxic effects at higher concentrations. At the anti-tumor level, aconitine regulates the [NF-κB](/ingredients/condition/inflammation) signaling pathway—reducing nuclear translocation of the p65 subunit—which in turn suppresses anti-apoptotic Bcl-2 expression while upregulating pro-apoptotic Bax, shifting the Bcl-2/Bax ratio toward programmed cell death and triggering [autophagy](/ingredients/condition/longevity)-mediated tumor cell clearance. Structural features critical to bioactivity include the moderate basicity of the nitrogen atom, its compact spatial configuration, and the introduction of hydroxyl, carbonyl, or alkene groups at the C3 position; conversely, hydrophilic substituents at positions C2, C3 (A ring) and C8, C15 (C ring) are implicated in neurological toxicity through enhanced CNS penetration and channel hyperstimulation. Aconitine and its derivatives also modulate intracellular calcium homeostasis, as evidenced by increased calcium transient frequency in hiPSC-cardiomyocytes at 5 μM, and suppress steroidogenic enzyme expression, reflecting pleiotropic activity across ion channel, transcription factor, and endocrine signaling networks.

## Clinical Summary

No rigorous human clinical trials have been conducted on aconitine itself as an isolated compound for any therapeutic indication, reflecting the compound's narrow therapeutic index and well-documented toxicity risk in unmodified form. Clinical applications in China involve pharmaceutical-grade derivatives—bulleyaconitine A (from Aconitum bulleyanum) and related compounds—formulated as standardized injectable or oral analgesics, though internationally accessible RCT reports with defined sample sizes, validated outcome measures, and effect sizes remain limited. In vitro evidence from hiPSC-cardiomyocyte models at 5 μM demonstrates electrophysiological and calcium-handling effects within 5–30 minutes, providing mechanistic insight relevant to both therapeutic and toxicological risk assessment. Overall, confidence in clinical benefit for any specific human indication is low; aconitine's clinical relevance is primarily as a pharmacological template for derivative drug development rather than as a directly applicable therapeutic agent.

## Nutritional Profile

Aconitine is a pure alkaloid compound (C₃₄H₄₇NO₁₁, molecular weight 645.74 g/mol) and does not constitute a nutritional ingredient; it provides no macronutrients, vitamins, or minerals. As a diterpenoid alkaloid, it is characterized by a complex hexacyclic carbon skeleton bearing multiple ester groups (acetyl and benzoyl at C8 and C14), hydroxyl groups, and a tertiary amine nitrogen critical to its pharmacological and toxicological properties. Bioavailability is influenced by ester hydrolysis during processing or [digestion](/ingredients/condition/gut-health)—thermal hydrolysis converts the diester (highly toxic aconitine) to monoester benzoylaconine (intermediate toxicity) and then to aconine (low toxicity), dramatically altering the pharmacokinetic profile. In whole Aconitum plant material, aconitine co-occurs with related alkaloids including mesaconitine, hypaconitine, neoline, fuziline, and lappaconitine, each with distinct potency and safety profiles that collectively define the plant's pharmacological activity.

## Dosage & Preparation

- **Traditional Decoction (Processed Root)**: In Traditional Chinese Medicine, aconitine-containing fuzi (processed Aconitum carmichaelii root) is used in decocted herbal formulas at 3–15 g of prepared root per dose; prolonged boiling (30–60 minutes) hydrolyzes aconitine to less toxic benzoylaconine and aconine metabolites, reducing potency and risk.
- **Pharmaceutical Analgesic Tablets (Bulleyaconitine A)**: The clinical derivative bulleyaconitine A is formulated in China as oral tablets (4 mg per tablet) dosed at 4–8 mg per dose, 2–3 times daily under medical supervision for chronic pain indications.
- **Injectable Pharmaceutical Forms**: Lappaconitine hydrobromide is available as a pharmaceutical injectable in certain markets, dosed strictly under clinical supervision with weight-based calculations; standardized to defined alkaloid content.
- **No Established Supplemental Dose**: There is no validated or safe supplemental dose for isolated aconitine in dietary supplement form; the compound is not appropriate for self-administration outside of rigorously controlled pharmaceutical contexts.
- **Standardization**: Analytical-grade aconitine used in research is quantified by HPLC with UV or mass spectrometric detection; pharmacopeial standards for Aconitum herbal preparations typically specify maximum aconitine-type alkaloid content (e.g., Chinese Pharmacopoeia limits total diester alkaloids to ≤0.020% in processed fuzi).
- **Timing Note**: Cardiotoxic and neurotoxic effects of aconitine manifest rapidly after absorption (onset within minutes to 1 hour in poisoning cases), underscoring the critical importance of controlled processing and dose precision in any legitimate application.

## Safety & Drug Interactions

Aconitine is among the most acutely toxic plant alkaloids known, with an estimated lethal oral dose of 2–6 mg in adults; toxicity is dose-dependent and manifests as paresthesia, nausea, severe ventricular arrhythmias (including ventricular tachycardia and fibrillation), hypotension, and respiratory paralysis, with cardiac and neurological effects appearing within 10–20 minutes of significant exposure. Aconitine is absolutely contraindicated in pregnancy and lactation, in individuals with pre-existing cardiac arrhythmias, heart block, or structural heart disease, and in patients with impaired hepatic [metabolism](/ingredients/condition/weight-management); the compound has a narrow therapeutic index with no established safe supplemental dose for human consumption outside of rigorously processed and standardized pharmaceutical formulations. Clinically significant drug interactions include additive cardiotoxicity risk with Class I and III antiarrhythmics (e.g., flecainide, amiodarone), digoxin, and any QT-prolonging agents; co-administration with CYP3A4 inhibitors (e.g., azole antifungals, macrolide antibiotics) may reduce metabolic clearance and potentiate toxicity. Regulatory agencies including the U.S. FDA and European Medicines Agency classify aconitine-containing raw plant materials as unsafe for unprocessed supplemental use, and multiple fatalities from accidental or intentional ingestion of aconite-containing products are documented in the medical literature.

## Scientific Research

The evidence base for aconitine consists almost entirely of in vitro cellular studies, animal pharmacokinetic experiments, and computational molecular docking analyses, with no large-scale randomized controlled trials (RCTs) conducted on the native compound in humans due to its established toxicity. A meta-analysis aggregating 37 preclinical studies provided the strongest systematic evidence for anti-tumor activity, demonstrating consistent findings of reduced tumor proliferation, increased apoptosis rates, and altered Bcl-2/Bax expression, though the inherent limitations of preclinical meta-analyses—including publication bias and lack of human translation—substantially constrain confidence. Pharmacokinetic data from animal models indicate dose-dependent increases in Cmax (1.28 μg/L at 0.5 g/kg to 1.69 μg/L at 1.0 g/kg) and notable prolongation of half-life at higher doses (t½z increasing from 1.90 to 7.53 hours), suggesting nonlinear kinetics that complicate dose extrapolation to humans. Clinical-stage evidence exists only for structurally modified derivatives such as bulleyaconitine A and lappaconitine, which have undergone pharmaceutical development in China for analgesic indications, but peer-reviewed RCT data with defined effect sizes and sample sizes for these agents are not widely available in international literature.

## Historical & Cultural Context

Aconitum species have been documented in traditional medicine systems across Asia and Europe for over two millennia; in Traditional Chinese Medicine, processed aconite root (fuzi, pao fu zi) is one of the most important yang-restoring herbs, appearing prominently in classical formularies including Zhang Zhongjing's Shang Han Lun (c. 200 CE), where it featured in formulas for cold-pattern pain, heart failure, and shock-like states. In Ayurvedic medicine, Aconitum ferox (vatsanabha) was traditionally purified through elaborate shodhana processing—boiling in cow's milk, ghee, or herbal decoctions—to reduce toxicity before use in low doses as a nervine, analgesic, and fever remedy. European monkshood (Aconitum napellus) was historically termed 'queen of poisons' and 'wolf's bane'; its alkaloids were used in homicidal poisoning in antiquity, documented by Dioscorides and Pliny the Elder, and were later studied by Rudolf Böhm and others in the 19th century, leading to the isolation and characterization of aconitine by Geiger and Hesse in 1833. The compound's extreme toxicity—with a lethal dose in humans estimated at 2–6 mg of pure aconitine orally—has historically limited therapeutic use to processed, detoxified preparations, and modern pharmaceutical interest has pivoted toward synthesizing safer structural analogs that retain analgesic and anti-cancer scaffold properties.

## Synergistic Combinations

In Traditional Chinese Medicine, aconitine-containing fuzi is classically paired with Glycyrrhiza uralensis (licorice root) in formulations such as Sini Tang; glycyrrhizin and related triterpenoid saponins in licorice have been experimentally shown to modulate aconitine absorption kinetics and reduce cardiotoxic effects, potentially through CYP enzyme induction and direct alkaloid binding interactions. Preclinical research on aconitine derivatives in anti-cancer contexts suggests potential additive or synergistic effects when combined with conventional chemotherapy agents that also target Bcl-2 (e.g., venetoclax-class compounds) or Hsp90 inhibitors, given the complementary binding modes demonstrated by aconitine scaffold compound 27 at the Hsp90α ATP-binding site. Dry ginger (Zingiber officinale, gan jiang) is another classical TCM co-herb used with aconite preparations; gingerols may partially mitigate aconitine-associated gastrointestinal irritation and are hypothesized to provide pharmacodynamic buffering through independent [anti-inflammatory](/ingredients/condition/inflammation) sodium channel interactions, though rigorous pharmacokinetic synergy data in humans remain unavailable.

## Frequently Asked Questions

### Is aconitine safe to take as a supplement?

No—aconitine in its unprocessed form is one of the most acutely toxic plant alkaloids known, with a lethal human dose estimated at just 2–6 mg orally. It is not approved as a dietary supplement by the FDA or EMA, and its use is restricted to pharmaceutical-grade processed derivatives (such as bulleyaconitine A) under strict medical supervision in certain countries. Self-administration of raw aconitine or unprocessed aconite products carries a serious risk of fatal cardiac arrhythmia and neurological toxicity.

### What is aconitine used for in traditional medicine?

In Traditional Chinese Medicine, processed aconite root (fuzi) has been used for over 2,000 years for cold-pattern pain, heart failure-like syndromes, and arthritis, always after prolonged boiling that converts toxic aconitine to less toxic metabolites like benzoylaconine. Ayurvedic medicine similarly uses shodhana-purified Aconitum ferox in micro-doses for pain and fever. Both systems emphasize that processing is essential and that raw aconitine itself is never used therapeutically in its pure form.

### How does aconitine work as a painkiller?

Aconitine produces analgesic effects primarily by binding to and modulating voltage-gated sodium channels (particularly Nav1.4 and Nav1.7), altering their activation threshold and prolonging inactivation, which reduces the ability of peripheral sensory neurons to propagate pain signals to the central nervous system. Additionally, its anti-inflammatory action via NF-κB pathway suppression reduces local mediators that sensitize nociceptors. However, this same sodium channel mechanism underlies its serious cardiac and neurotoxic risks, making the therapeutic window extremely narrow for the native compound.

### What are the symptoms of aconitine poisoning?

Aconitine poisoning typically presents within 10–20 minutes of ingestion and initially causes intense tingling and numbness of the lips, tongue, and extremities (paresthesia), followed by nausea, vomiting, diaphoresis, and weakness. Severe cases progress to life-threatening ventricular arrhythmias (ventricular tachycardia or fibrillation), hypotension, bradycardia, and respiratory muscle paralysis; death can occur within hours without emergency intervention. Multiple fatalities from accidental or intentional consumption of aconite-containing herbal products are documented globally, and any suspected aconitine exposure requires immediate emergency medical evaluation.

### Are there any pharmaceutical drugs derived from aconitine?

Yes—several structurally modified aconitine derivatives have been developed into pharmaceutical agents, primarily in China. Bulleyaconitine A (from Aconitum bulleyanum) is approved in China as an oral analgesic tablet for chronic pain conditions, and lappaconitine hydrobromide is used as a pharmaceutical-grade analgesic and antiarrhythmic agent. Researchers have also synthesized novel aconitine scaffold derivatives targeting Hsp90α (with IC₅₀ values as low as 0.71 nM in preclinical models) as potential anti-cancer leads, though none of these advanced derivatives have yet reached international clinical approval.

### What is the difference between aconitine and its pharmaceutical derivatives like bulleyaconitine A?

Aconitine is the naturally occurring alkaloid found in Aconitum species plants, while bulleyaconitine A and other derivatives are chemically modified versions engineered to enhance safety and efficacy. These pharmaceutical derivatives, such as compounds 15 and 37 class analogues, maintain the analgesic properties of aconitine by binding to voltage-gated sodium channels but are designed with reduced toxicity profiles for clinical use. Several aconitine-type derivatives have achieved clinical-stage approval in China as formulated pharmaceutical analgesics.

### How does aconitine's mechanism differ between pain relief and potential anti-tumor effects?

Aconitine reduces pain by binding to voltage-gated sodium channels and decreasing neuronal excitability, which suppresses pain signal transmission. In contrast, its anti-tumor effects operate through a distinct mechanism involving inhibition of tumor cell proliferation, suggesting aconitine interacts with multiple cellular pathways beyond its primary analgesic action. These dual mechanisms indicate aconitine alkaloids may have broader therapeutic potential than pain management alone.

### Why is aconitine more likely to be used as a pharmaceutical derivative rather than a raw plant extract?

Aconitine's narrow therapeutic window and high toxicity risk make it unsuitable as a raw supplement, as traditional plant extracts contain unpredictable alkaloid concentrations that easily lead to poisoning. Pharmaceutical derivatives undergo chemical modification and standardization to optimize the sodium channel-binding properties responsible for analgesia while significantly reducing systemic toxicity. This controlled formulation approach allows aconitine-type compounds to deliver therapeutic benefits with manageable safety profiles in regulated clinical settings.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*